Suspend in haste: Physicians rue Indian pioglitazone decision
This article was originally published in Scrip
Executive Summary
Leading Indian physicians believe that India's move to suspend the sale of the diabetes drug, pioglitazone, and its combinations has been done in haste and in the absence of compelling evidence that strongly establishes the correlation of the drug with the risk of bladder cancer in the Indian population.